Login
$SLN
$19.83 -$0.00 (0.03%) Live

$SLN 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

LONDON, Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided ...

19 Oct 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

THIS TRANSACTION AGREEMENT (this “Agreement”), dated as of October 18, 2026, is by and between MERCK KGAA, DARMSTADT, GERMANY, a German corporation with general partners (“Purchaser”), and SILENCE THERAPEUTICS PLC, a public limited compa...

12 Aug 2026 8-K: Entry into a Material Definitive Agreement; Other Events

12,962,963 AMERICAN DEPOSITARY SHARES OF THE COMPANY, EACH REPRESENTING THREE ORDINARY SHARES, NOMINAL VALUE £0.05 PER SHARE

10 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO

10 Aug 2026 8-K: Results of Operations and Financial Condition

LONDON, Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026.

23 Jun 2026 8-K: Regulation FD Disclosure

Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or ...

16 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 16, 2026, Silence Therapeutics plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the nine resolutions set forth below, each of which was voted on and duly passed on ...

11 Jun 2026 8-K: Other Events

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

18 May 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

On May 18, 2026, Silence Therapeutics plc (the “Company” or “we”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”). Under the Sales Agreement, the Company may offer and sell, from time...

07 May 2026 8-K: Results of Operations and Financial Condition

Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026

05 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

22 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 18, 2025, the Board of Directors (the “Board”) of Silence Therapeutics plc (the “Company”) appointed Rhonda Hellums, the Company’s Executive Vice President and Chief Financial Officer, to the Board, effectively immediately. I...

15 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company’s Pres...

06 Nov 2025 8-K: Results of Operations and Financial Condition

SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026

23 Oct 2025 8-K: Other Events

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

14 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

07 Aug 2025 8-K: Results of Operations and Financial Condition

LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the second quarter ended June ...

27 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 26, 2025, Silence Therapeutics plc (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the thirteen resolutions set forth below, each of which was voted on and duly passed...

08 May 2025 8-K: Results of Operations and Financial Condition

LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March ...

06 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support